These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33517222)

  • 1. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling.
    Shentu Y; Li Y; Xie S; Jiang H; Sun S; Lin R; Chen C; Bai Y; Zhang Y; Zheng C; Zhou Y
    Int Immunopharmacol; 2021 Apr; 93():107374. PubMed ID: 33517222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
    Balzer MS; Rong S; Nordlohne J; Zemtsovski JD; Schmidt S; Stapel B; Bartosova M; von Vietinghoff S; Haller H; Schmitt CP; Shushakova N
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin attenuates epithelial-to-mesenchymal transition through senescence in peritoneal dialysis.
    Lho Y; Park Y; Do JY; Kim AY; Park YE; Kang SH
    Am J Physiol Renal Physiol; 2024 Sep; 327(3):F363-F372. PubMed ID: 38961839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2.
    Zhou Y; Fan J; Zheng C; Yin P; Wu H; Li X; Luo N; Yu X; Chen C
    Biomed Pharmacother; 2019 Jan; 109():1327-1338. PubMed ID: 30551383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parthenolide, an NF-κB inhibitor, alleviates peritoneal fibrosis by suppressing the TGF-β/Smad pathway.
    Zhang Y; Huang Q; Chen Y; Peng X; Wang Y; Li S; Wu J; Luo C; Gong W; Yin B; Xiao J; Zhou W; Peng F; Long H
    Int Immunopharmacol; 2020 Jan; 78():106064. PubMed ID: 31838448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway.
    Huang Q; Chen J; Liao S; Long J; Fang R; He Y; Chen P; Liu D
    Biogerontology; 2024 Jun; 25(3):567-581. PubMed ID: 38403802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of thrombospondin-1 ameliorates high glucose-induced peritoneal fibrosis through downregulation of TGF-β1/Smad3 signaling pathway.
    Jiang N; Zhang Z; Shao X; Jing R; Wang C; Fang W; Mou S; Ni Z
    J Cell Physiol; 2020 Jan; 235(1):364-379. PubMed ID: 31236971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
    Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
    Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy promotes fibrosis and apoptosis in the peritoneum during long-term peritoneal dialysis.
    Wu J; Xing C; Zhang L; Mao H; Chen X; Liang M; Wang F; Ren H; Cui H; Jiang A; Wang Z; Zou M; Ji Y
    J Cell Mol Med; 2018 Feb; 22(2):1190-1201. PubMed ID: 29077259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-methylpiperazine-diepoxyovatodiolide ameliorates peritoneal fibrosis via suppressing TGF-β/Smad and JAK/STAT signaling pathway.
    Mo M; Zeng Y; Zeng Y; Li S; He X; Chen X; Luo Q; Liu M; Luo C; Dou X; Peng F; Long H
    Chem Biol Interact; 2023 Sep; 382():110589. PubMed ID: 37268199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parthenolide alleviates peritoneal fibrosis by inhibiting inflammation via the NF-κB/ TGF-β/Smad signaling axis.
    Zhang Y; Feng W; Peng X; Zhu L; Wang Z; Shen H; Chen C; Xiao L; Li S; Zhao Y; Lin M; Huang Y; Long H; Liang J
    Lab Invest; 2022 Dec; 102(12):1346-1354. PubMed ID: 36307537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silymarin ameliorates peritoneal fibrosis by inhibiting the TGF-β/Smad signaling pathway.
    Bai Y; Wang L; TingYang ; Wang L; Ge W
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2379-2391. PubMed ID: 37052642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis.
    Costalonga EC; de Freitas LJ; Aragone DDSP; Silva FMO; Noronha IL
    PLoS One; 2017; 12(9):e0184302. PubMed ID: 28873458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro.
    Duan WJ; Yu X; Huang XR; Yu JW; Lan HY
    Am J Pathol; 2014 Aug; 184(8):2275-84. PubMed ID: 24925688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of TGF-beta1/Smads in the development of peritoneal fibrosis induced by high glucose peritoneal dialysate and LPS].
    Dou XR; Yu XQ; Li XY; Chen WF; Hao WK; Jia ZJ; Peng WX; Wang X; Yin PD; Wang WJ; Zheng ZH
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2613-8. PubMed ID: 16321321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates epithelial-mesenchymal transition of peritoneal mesothelial cells and M2 macrophage polarization.
    Hu Y; Zhou C; Zhong Q; Li X; Li J; Shi Y; Ma X; Jiang D; Wang Y; Zhuang S; Liu N
    Ren Fail; 2024 Dec; 46(2):2392849. PubMed ID: 39165231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the therapeutic effects and mechanisms of Roxadustat on peritoneal fibrosis Based on the TGF-β/Smad pathway.
    Wang L; Fan J; Yang T; Shen J; Wang L; Ge W
    Biochem Biophys Res Commun; 2024 Jan; 693():149387. PubMed ID: 38145606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitro-oleic acid inhibits the high glucose-induced epithelial-mesenchymal transition in peritoneal mesothelial cells and attenuates peritoneal fibrosis.
    Su W; Wang H; Feng Z; Sun J
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F457-F467. PubMed ID: 31760768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling.
    Ueno T; Nakashima A; Doi S; Kawamoto T; Honda K; Yokoyama Y; Doi T; Higashi Y; Yorioka N; Kato Y; Kohno N; Masaki T
    Kidney Int; 2013 Aug; 84(2):297-307. PubMed ID: 23486522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.